Long-term safety of mycophenolate mofetil and cyclosporine: A review

Journal of Drugs in Dermatology

Volumn 7, Issue 8, 2008, Pages 741-748

  Buell, Catherine ^a   Koo, John ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DERMATOLOGICAL AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; INFECTION; LONG TERM CARE; META ANALYSIS; NEOPLASM; PREGNANCY; PSORIASIS; REVIEW; SAFETY;

ADULT; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; LONG-TERM CARE; MYCOPHENOLIC ACID; NEOPLASMS; PREGNANCY; PSORIASIS; SAFETY;

EID: 55249106262     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Jones EL, Epinette WW, Hackney VC, et al. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol. 1975;65:537-542.
2. Laburte C, Grossman R, Abi-Rached J, et al. Efficacy and safety of oral cyclosporine A (CyA;Sandimmune) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol. 1994;130:366-375. (Pubitemid 24204648)
3. Vernino S, Salomao DR, Habermann TM, et al. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005;65:639-641. (Pubitemid 41170735)
4. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Transplantation. 1998;65:1450-1454. (Pubitemid 28285243)
5. Brenan DC, Rodeheffer RJ, Ambinder RF. Development of malignancy following solid organ transplantation. UpToDate Online. Available at: http://www.utdol.com/online/content/topic.do?topicKey=renltran/ 11791&selectedTitle=1~150&source=search-result. Accessed July 15, 2008.
6. Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exper Dermatol. 2006;32:23-27.
7. Grundmann-Kollman M, Podda M, Oschsendorf F, et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol. 2001;137:870-873. (Pubitemid 32641646)
8. Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005;112:1472-1477. (Pubitemid 41074642)
9. Marinari R, Fleischmajer R, Schragger AH, et al. Mycophenolic acid in the treatment of psoriasis - long-term administration. Arch Dermatol. 1977;113:930-932. (Pubitemid 8146834)
10. Sievers TM, Rossi SJ, Ghobrial RM, et al. Mycophenolate mofetil. Pharmacotherapy. 1997;17:1178-1197. (Pubitemid 27518030)
11. Loftus CG, Egan LJ, Sandborn WJ, et al. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin N Am. 2004;33:141-169. (Pubitemid 38737265)
12. Roche CellCept Drug Information. Federal Drug Administration Website. Available at: www.fda.gov/medwatch/SAFETY/2005/Oct-PI/CellCept-PI.pdf. Accessed July 15, 2008.
13. Pareja-Cuiro F, Serrano Diez-Canedo J, Gomez-Bravo MA, et al. Efficacy and safety of mycophenolate mofetil as part of induction therapy in liver transplantation. Transplant Proc. 2005;37:3926-3929. (Pubitemid 43015214)
14. Mimouni D, Anhalt GJ, Cummins DL, et al. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139:739-742. (Pubitemid 36705940)
15. Chams-Davatchi C, Nonahal Azar R, Daneshpazooh M, et al. Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris. Annales Dermatol Venereologie. 2002;129:23-35.
16. Neuber K, Schwartz I, Itschert G, et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143:385-391. (Pubitemid 30650410)
17. Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy out-comes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698-1702. (Pubitemid 46035654)
18. Koo JY, Kadonaga JN, Wintroub BV, et al. The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol. 1992;26:836-840.
19. Bagot M, Dubertret L. Lymphocytic infiltrates of the skin in association with cyclosporine therapy [letter]. J Am Acad Dermatol. 1992;26:283.
20. Yamamoto T, Katayama I, Nishioka K. Adenocarcinoma of the mouth in a patient with psoriasis under short-term cyclosporine therapy. Dermatology. 1996;193:72-73. (Pubitemid 26257107)
21. Ohtsuki M, Nakagawa H, Sugai J, et al. Long-term continuous versus intermittent cyclosporine: therapy for psoriasis. J Dermatol. 2003;30:290-298. (Pubitemid 36554137)
22. Massouye I, Salamon D, Saurat J-H. B-cell lymphoma after cyclosporine for keratosis lichenoides chronica. Arch Dermatol. 1993;129:914-915. (Pubitemid 23206030)
23. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 year cohort study. J Invest Dermatol. 2003;120:211-216. (Pubitemid 36513069)
24. van den Borne BEEM, Landewe RBM, Houkes I, et al. No increased risk of malignancies and mortality in cyclosporine A-treated patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:1930-1937. (Pubitemid 28506681)
25. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 2000;42:177-186.
26. Cockburn ITR, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmunity. 1989;2:723-731.
27. Penn I. Cancers following cyclosporine therapy. Transplantation. 1987;43:32-35. (Pubitemid 17002451)
28. Magee CC. Pharmacology and side effects of cyclosporine and tacrolimus. UpToDate Online. Available at: http://www.utdol.com/online/content/topic.do? topicKey=tx-rheum/8690&selectedTitle=2~150&source=search-result. Accessed July 15, 2008.
29. Zachariae H, Kragballe, K, Hansen HE, et al. Renal biopsy finding in long-term cyclosporine treatment of psoriasis. Br J Dermatol. 1997;136:531-535. (Pubitemid 27160326)
30. Powles AV, Hardman CM, Porter WM, et al. Renal function after 10 years' treatment with cyclosporine for psoriasis. Br J Dermatol. 1998;138:443-449. (Pubitemid 28145512)
31. Ho VCY, Griffiths CEM, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001;44:643-651. (Pubitemid 32249523)
32. Powles AV, Carmichael D, Hulme B, et al. Renal function after long-term low-dose cyclosporine for psoriasis. Br J Dermatol. 1990;122:665-669. (Pubitemid 20153664)
33. Christophers E, Mrowietz U, Henneicke HH, et al. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. J Am Acad Dermatol. 1992;26:86-90.
34. Schrem H, Luck R, Becker T, et al. Update on liver transplantation using cyclosporine. Transplantation Proceedings. 2004;36:2525-2531. (Pubitemid 40036770)
35. Raddadi AA, Baker DZ. Cyclosporine and pregnancy. Br J Dermatol. 1999;140:1197-1198.
36. Finch TM, Tan CY. Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporine A. Br J Dermatol. 2000;142:582.
37. Armenti VT, Radomski, JS, Moritz MJ, et al. Chapter 9. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of Pregnancy after Transplantation. In: Cecka & Terasaki, eds. Clinical Transplants 2004. UCLA Immunogenetics Center, Los Angeles, CA; 2004:103-114.
38. Novartis. Sandimmune Information. Federal Drug Administration Website. REV: Dec 2002. USA T2002-89. #89016102. Available at: www.fda.gov/medwatch/ SAFETY/2004/feb-Pl/Sandimmune-P1.pdf. Accessed June 27, 2006.
39. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol. 1993;11:S117-119.
40. Marci I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358:1042-1045. (Pubitemid 32925124)
41. Geilen CC. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol. 2001;144:583-586. (Pubitemid 32232016)
42. Grundmann-Kollmann M, Mooser G, Schraeder P, et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol. 2000;42:835-837. (Pubitemid 30252894)
43. Zhou Y, Rosenthal D, Dutz J, Ho V. Mycophenolate mofetil (Cell-Cept) for psoriasis: A two-center, prospective, open-label clinical trial. J Cutan Med Surg. 2003;7:193-197. (Pubitemid 36859095)
44. Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis. Br J Derm. 2001;144:638-639.
45. Pickenacker A, Luger TA, Scharz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol. 198;134:378-379.
46. Grundmann-Kollmann M, Treatment of Pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol. 1999;135:724-725. (Pubitemid 29277853)
47. Bohm M, Beissert S, Schwarz T, et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet. 1997;349:541. (Pubitemid 27092798)
48. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40:957-960. (Pubitemid 29268927)
49. Megahed M, Schmiedenberg S, Becker J, Ruziscka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroidsparing agent. J Am Acad Dermatol. 2001;45:256-259. (Pubitemid 32729310)
50. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol. 2001;45:142-144. (Pubitemid 32655712)
51. Lee MR, Cooper AJ. Mycophenolate mofetil in pyoderma gangrenosum. Treatment. 2004;15:303-307. (Pubitemid 39423289)
52. Bubul Baskan E, Sarlcoglu H, Tunal S, Tolunay S. Effective tx of relapsing idiopathic nodular panniculits (Pfeifer-Weber-Christian disease) with mycophenolate mofetil. J Dermatol Treatment. 2003;14:57-60. (Pubitemid 36417431)
53. Pons S, Praga M, Izquierdo Garcia E, et al. Efficacy and safety of "rescue therapy" with mycophenolate mofetil in resistant primary glomerulonephritis - A multicenter study. Nephrol Dial Transplant. 2007;22:1351-1360. (Pubitemid 47072223)
54. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well-tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2007;130:30-36. (Pubitemid 44116838)